On May 27, 2015, an order regarding the motion/application for approval of a settlement pursuant to rule 9019 was filed in the bankruptcy case of Dendreon Corporation and its affiliates.
The filing was assigned docket number 729 and is described on the court’s official docket as follows:
Order Approving Stipulation Of Settlement Between GlaxoSmithKline LLC And The Debtors Resolving The Debtors’ Objection To Claim Of GlaxoSmithKline LLC Under 11 U.S.C. §§ 105(A) And 502 And Fed. R. Bankr. P. 3007.(related document(s), ) Order Signed on 5/27/2015. (Attachments: # (1) Exhibit 1) (NAB)
Dendreon Corporation filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on November 10, 2014. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 14-12515. The bankruptcy case is currently assigned to United States Bankruptcy Judge Peter Walsh. The law firm of Skadden, Arps, Slate, Meagher & Flom LLP is acting as lead bankruptcy counsel to Dendreon Corporation in the bankruptcy case.